` SERA (Sera Prognostics Inc) vs S&P 500 Comparison - Alpha Spread

SERA
vs
S&P 500

Over the past 12 months, SERA has underperformed S&P 500, delivering a return of -55% compared to the S&P 500's +14% growth.

Stocks Performance
SERA vs S&P 500

Loading
SERA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SERA vs S&P 500

Loading
SERA
S&P 500
Difference
www.alphaspread.com

Performance By Year
SERA vs S&P 500

Loading
SERA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sera Prognostics Inc vs Peers

S&P 500
SERA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sera Prognostics Inc
Glance View

Market Cap
138.8m USD
Industry
Biotechnology

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

SERA Intrinsic Value
1.69 USD
Overvaluation 53%
Intrinsic Value
Price
Back to Top